{"entity":{"id":"nct06224257","kind":"trial","name":"Efficacy and Safety of Linperlisib in Relapsed/Refractory Large Granular T Lymphocytic Leukemia","aka":[],"tldr":"A phase 2 trial of Linperlisib in Leukaemia, run by Institute of Hematology & Blood Diseases Hospital, China, now recruiting.","summary":"Efficacy and Safety of Linperlisib in Relapsed/Refractory Large Granular T Lymphocytic Leukemia is a phase 2 interventional study registered as NCT06224257 by Institute of Hematology & Blood Diseases Hospital, China, with 41 participants planned, started 2023-12-03 and due to reach its primary completion in 2025-10-31. Interventions recorded: Linperlisib. Conditions recorded: Relapsed/Refractory Large Granular T Lymphocytic Leukemia.\n\nLinked to the drug Linperlisib because the registry names it among its interventions and Leukaemia among its conditions. Registry record only: no result has been read by an editor.","status":"recruiting","asOf":"2026-09-22","links":[{"label":"ClinicalTrials.gov NCT06224257","url":"https://clinicaltrials.gov/study/NCT06224257"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["leukaemia"],"sections":[],"technologies":[],"targets":[],"drugs":["linperlisib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06224257","phase":"2","setting":"A Phase 2, Multicenter, Single-arm, Open-label Study on the Efficacy and Safety of PI3K Inhibitors in Relapsed/Refractory Large Granular T Lymphocytic Leukemia","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","participation":[{"nct":"NCT06224257","source":"https://clinicaltrials.gov/study/NCT06224257","fetchedAt":"2026-10-07T16:54:19.620Z","studySha256":"42ddb45eaa09ab318c1686c5bfadcdffc1f337b5b20c5f0076c345602f6811a5","overallStatus":"RECRUITING","lastUpdatePosted":"2025-08-05","leadSponsor":"Institute of Hematology & Blood Diseases Hospital, China","collaboratorCount":1,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":41,"enrolmentType":"ESTIMATED","siteCount":3,"recruitingSiteCount":3,"countries":["China"]}],"started":"2023-12-03","startedType":"actual","enrolled":41,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06224257/","neighbours":{"cancer":[{"id":"leukaemia","kind":"cancer","name":"Leukaemia (all types)","route":"/cancers/leukaemia/"},{"id":"t-large-granular-lymphocytic-leukaemia","kind":"cancer","name":"T-cell large granular lymphocytic leukaemia","route":"/cancers/t-large-granular-lymphocytic-leukaemia/"}],"drug":[{"id":"linperlisib","kind":"drug","name":"Linperlisib","route":"/drugs/linperlisib/"}]}}